Kopp Investment Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Kopp Investment Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,806	Closed	-$227K	–	68
2017 Q3	$227K	Buy	3,806 +746	+24%	+$45.1K	0.21%	59
2017 Q2	$241K	Buy	3,060 +10	+0.3%	+$818	0.22%	56
2017 Q1	$253K	Sell	3,050 -855	-22%	-$63.6K	0.25%	56
2016 Q4	$310K	Sell	3,905 -405	-9%	-$29.4K	0.33%	55
2016 Q3	$302K	Buy	+4,310	New	+$239K	0.3%	55
2016 Q2	–	Sell	-5,388	Closed	-$218K	–	66
2016 Q1	$218K	Buy	5,388 +30	+0.6%	+$1.9K	0.12%	61
2015 Q4	$475K	Hold	5,358	–	–	0.23%	54
2015 Q3	$397K	Buy	5,358 +306	+6%	+$25.5K	0.21%	53
2015 Q2	$409K	Sell	5,052 -6,873	-58%	-$448K	0.18%	56
2015 Q1	$500K	Buy	+11,925	New	+$338K	0.22%	57

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kopp Investment Advisors's EGRX Position: Q4 2017 in Review

Kopp Investment Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2017, closing a stake of 3,806 shares — an estimated $227K sold.

Kopp Investment Advisors first reported a position in EGRX in Q1 2015 and held it in 10 quarters. The position peaked at $500K in Q1 2015. 170 funds tracked by Wall St. Rank hold EGRX as of Q4 2017.

Kopp Investment Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Kopp Investment Advisors sold 3,806 Eagle Pharmaceuticals, Inc. shares in Q4 2017, an estimated $227K.
Kopp Investment Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 10 quarters.
Kopp Investment Advisors's Eagle Pharmaceuticals, Inc. position peaked at $500K in Q1 2015.
170 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2017.

Based on Kopp Investment Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.